Dynamic predictive probabilities to monitor rapid cystic fibrosis disease progression. by Szczesniak, Rhonda D et al.
LSHTM Research Online
Szczesniak, Rhonda D; Su, Weĳi; Brokamp, Cole; Keogh, Ruth H; Pestian, John P; Seid, Michael;
Diggle, Peter J; Clancy, John P; (2019) Dynamic predictive probabilities to monitor rapid cystic fibrosis
disease progression. Statistics in medicine. ISSN 0277-6715 DOI: https://doi.org/10.1002/sim.8443
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655605/
DOI: https://doi.org/10.1002/sim.8443
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
Received: 29 May 2019 Revised: 23 September 2019 Accepted: 16 November 2019
DOI: 10.1002/sim.8443
RE S EARCH ART I C L E
Dynamic predictive probabilities to monitor rapid cystic
fibrosis disease progression
Rhonda D. Szczesniak1 Weiji Su2 Cole Brokamp1 Ruth H. Keogh3
John P. Pestian4 Michael Seid5 Peter J. Diggle6 John P. Clancy7,8
1Division of Biostatistics & Epidemiology,
Cincinnati Children's Hospital Medical
Center and Department of Pediatrics,
University of Cincinnati, Cincinnati, Ohio
2Department of Mathematical Sciences,
University of Cincinnati, Cincinnati, Ohio
3Department of Medical Statistics,
London School of Hygiene and Tropical
Medicine, London, UK
4Division of Biomedical Informatics,
Cincinnati Children's Hospital Medical
Center, and Department of Pediatrics,
University of Cincinnati, Cincinnati, Ohio
5James M. Anderson Center for Health
Systems Excellence and Department of
Pediatrics, University of Cincinnati,
Cincinnati, Ohio
6CHICAS, Lancaster Medical School
Lancaster University Lancaster, UK and
Health Data Research UK, London, UK
7Division of Pulmonary Medicine,
Cincinnati Children's Hospital Medical
Center and Department of Pediatrics,
University of Cincinnati, Cincinnati, Ohio
8Cystic Fibrosis Foundation, Bethesda,
Maryland
Correspondence
Rhonda Szczesniak, Division of
Biostatistics & Epidemiology, Cincinnati
Children's Hospital Medical Center, 3333
Burnet Ave (MLC 5041), Cincinnati,
OH 45229.
Email: rhonda.szczesniak@cchmc.org
Funding information
National Heart, Lung, and Blood Institute,
K25 HL125954; National Heart, Lung, and
Blood Institute, R01 HL141286
Abstract
Cystic fibrosis (CF) is a progressive, genetic disease characterized by fre-
quent, prolonged drops in lung function. Accurately predicting rapid underlying
lung-function decline is essential for clinical decision support and timely inter-
vention. Determining whether an individual is experiencing a period of rapid
decline is complicated due to its heterogeneous timing and extent, and error
component of the measured lung function. We construct individualized pre-
dictive probabilities for “nowcasting” rapid decline. We assume each patient's
true longitudinal lung function, S(t), follows a nonlinear, nonstationary stochas-
tic process, and accommodate between-patient heterogeneity through random
effects. Corresponding lung-function decline at time t is defined as the rate of
change, S′(t). We predict S′(t) conditional on observed covariate and measure-
ment history by modeling a measured lung function as a noisy version of S(t).
Themethod is applied to data on 30 879USCFRegistry patients. Results are con-
trasted with a currently employed decision rule using single-center data on 212
individuals. Rapid decline is identified earlier using predictive probabilities than
the center's currently employed decision rule (mean difference: 0.65 years; 95%
confidence interval (CI): 0.41, 0.89). We constructed a bootstrapping algorithm
to obtain CIs for predictive probabilities. We illustrate real-time implementation
with R Shiny. Predictive accuracy is investigated using empirical simulations,
which suggest this approach more accurately detects peak decline, compared
with a uniform threshold of rapid decline. Median area under the ROC curve
estimates (Q1-Q3)were 0.817 (0.814-0.822) and 0.745 (0.741-0.747), respectively,
implying reasonable accuracy for both. This article demonstrates how individ-
ualized rate of change estimates can be coupled with probabilistic predictive
inference and implementation for a useful medical-monitoring approach.
KEYWORD S
longitudinal data analysis, medical monitoring, nonstationary process, nowcasting,
predictive probability distributions
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1 INTRODUCTION
Cystic fibrosis (CF) is the most common life-shortening genetic disease inWhites, affecting an estimated 70 000 individu-
als worldwide.1 Patient registry data have been used for decades to advance therapeutics and care, steadily increasing the
life expectancy of individuals with CF.2 However, the clinical course of this chronic disease remains marked by progres-
sive loss of lung function and eventual respiratory failure. Rapid pulmonary decline, which is characterized by an initial
drop in lung function, that is, sustained over time, occurs predominantly during adolescence, and early adulthood,3-5 but
typically recurs throughout the lifespan.6,7 Rapid decline requires immediate clinical intervention to recover lung func-
tion, which is measured using FEV1 (forced expiratory volume in 1 second of percentage of predicted). Landmark studies
stemming from CF epidemiology and quality improvement have elucidated strong associations of clinical and demo-
graphic characteristics with rapid decline8,9 and caremanagement practices have been improved/modified based on these
observations.10 A single-center study that defined rapid decline as a decrease in FEV1 of more than 10% predicted within
the prior 12months from themaximum observed FEV1 showed that subsequently treating patients according to this deci-
sion rule corresponded to mean improvements in overall FEV1.11 A similar study at another CF center corroborated these
findings.12 Early detection of rapid decline or its impending onset would enable early treatment, and potentially preven-
tion. However, statistical methods for medical monitoring to guide the early detection of rapid CF lung-function decline
do not exist.
There are several national CF patient registries across the world, which obtain longitudinal data on key variables
including FEV1, and several studies have developed models for FEV1 trajectories over the CF life course.13 Repeated
measures of FEV1 are clearly correlated over time within an individual, and a random intercepts model14 has been
the most widely used approach to fit longitudinal lung-function data. Studies of the Danish and US CF registries ana-
lyzing longitudinal FEV1 using exponential covariance to model the longitudinal correlation rather than conventional
random intercepts alone found improvements in model fit and prediction.7,15 Subsequently, a systematic review used
a weighted analysis, which included parameter estimates and mean trajectories reported from 39 peer-reviewed arti-
cles, to estimate mean FEV1 trajectory over age. The review highlighted the nonlinear, heterogeneous nature of FEV1
decline between individuals and the range of analysis approaches undertaken amongst the studies.16 In another study
aimed at clustering trajectories of lung-function decline into phenotypes, we found that individuals with the highest pul-
monary function early in life tended to have rapid decline at a later age than more severe phenotypes; these individuals
with the later decline tended to experience the greatest losses over time.5 Although numerous studies shed light on the
nonlinear, heterogeneous nature of FEV1 decline, and the opportunities to assess lung function using various patient
registries, the results offer explanations—as opposed to predictions—about the clinical course of CF in the individual
patient.
The goal of this article is to describe the application of a nonstationary stochastic process model to obtain
individual-level predictions of being in a state of rapid decline in lung function as measured by FEV1. We refer to this as
“nowcasting,” and by focusing on the rate of change, we go beyond the typical pointwise prediction of the absolute level
of a longitudinal biomarker, which is often inadequate to guide clinical decision making. The notion of modeling uncer-
tainty of predicted values through a target-based probability rather than a pointwise confidence interval (CI) has existed
for decades.17 One example is interimmonitoring in clinical trials to compute the predictive probability of success (e.g., a
favorable response to treatment) given interim data.18 Previous studies have described approaches using continuous lon-
gitudinal biomarkers to predict changes in trajectories based on a binary decision rule that classifies individuals at a given
timepoint. Motivated by the need to monitor clinically meaningful changes over time in CD4 count trajectories fromHIV
patients, Foulkes et al19 proposed two different prediction-based classification approaches. Their application goal was to
predict whether or not CD4 count would exceed a clinically meaningful threshold (e.g., 200 cells/mm3) for each patient
over time. For the first approach, they dichotomized CD4 counts according to the threshold and fit a generalized linear
mixed effectsmodel on the binary responses;model-based probabilitieswere used to generate a receiver-operating charac-
teristic (ROC) curve. The second approach fit a linearmixed effectsmodel to observed longitudinal CD4 and then used the
predicted value and corresponding prediction variance to construct a rule for classification based on a threshold. A more
recently described approach, highlighted in a review by Albert, is to fit such two-stage models simultaneously through
shared randomparameters, whichwould alleviate calibration error induced using “plug-in” estimates of randomeffects.20
Li and Gatsonis21 combined multiple biomarker trajectories using scores from functional principal components analysis
and adjusted for possibility of verification bias, to develop a composite diagnostic marker for classifying patient-specific
diagnosis of cancer recurrence.
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Diggle et al22 recently extended predictive probabilities for monitoring renal failure using an estimate of the patient's
longitudinal glomerular filtration rate (GFR). They replaced the random slope term in the Gaussian random intercept
and slope model with an integrated continuous-time random walk. They evaluated a predictive probability distribution
for the patient-specific rate of change, to determine the probability that the patient's current rate of decrease in GFR
would exceed 5% per year. In this article, we apply the samemethodology in the CF context; using FEV1 as the biomarker,
we assume the true longitudinal lung function follows a process S(t) with corresponding rate of change S′(t). We con-
struct a noisy version of using a data model consisting of observed longitudinal FEV1, which is our noisy measurement
of lung function, and observed (also noisy) covariate information. By conditioning on relevant data, we can create a class
of target functions for prediction that is specific to rapid lung-function decline.
Translating these approaches into point of care is critical to the utility of real-time prediction models. Moni-
toring tools have been presented in the clinical literature, but have limited appearances in the statistical literature.
A recent clinical study, which was aimed at predicting late seizures after ischemic stroke using Cox proportional
hazard modeling, presented a downloadable smart phone app for making predictions with new patients.23 A joint
longitudinal-survival model for prostate cancer recurrence was accompanied by an online risk calculator, provid-
ing predictions of up to 3 years in advance.24 We translate the final prediction model for a rapid lung-function
decline into an app in R Shiny. Our app shows how to use this model as a dynamic prognostic tool for CF clinical
decision making.
In this novel application tailored to rapid CF disease progression, we construct predictive probabilities specific to
underlying rates of changewithin a given population.We build upon previous work by (i)modifying the target function to
generate predictive probabilities of rate of change in the patient-specificmean response S′(t); (ii) including a bootstrapping
algorithm that provides CIs for the predictive probabilities; (iii) providing a prediction model platform in R Shiny that
could be integrated into point of care.
The rest of the article is organized as follows. The following section details the motivating CF registry data. Section
3 introduces the linear mixed model setup specific to the CF application and describes the estimation of rapid decline
and methods used for assessment of model fit. In Section 4, we define the predictive probability of rapid decline under
uniform thresholds and personalized scenarios. We describe the bootstrapping algorithm used to provide CIs for the pre-
dictive probabilities and corresponding empirical simulations used to examine predictive performance. Individual patient
predictions, the clinical dashboard created with the R Shiny app and comparison to an existing clinical algorithm are
described in Section 5. We conclude in Section 6 with a discussion of how the presented approach differs from existing
methods, as well as clinical implications and future considerations to further extend the approach and improve utility
of the clinical dashboard. Supporting Information for this article include (i) R implementation code in Data S1; (ii) Sup-
porting Information on model diagnostics, held-out and forecast validation metrics and an overview of the Shiny app in
Data S2.
2 CYSTIC FIBROSIS REGISTRY DATA
Data were obtained from the US Cystic Fibrosis Foundation Patient Registry (CFFPR), which has been used to track out-
comes for more than 50 years and includes demographic and clinical encounter-level data obtained from patients at care
centers accredited by the Cystic Fibrosis Foundation.25 The analysis cohort used for this prediction modeling study con-
sisted of patients with a valid CF diagnosis who were presumed “at risk” for rapid decline and followed in the CFFPR
between January 1, 2003 and December 31, 2015. We considered available data from 2003 onward because most relevant
predictors of rapid decline were consistently documented at each clinical encounter—as opposed to annually—beginning
in 2003. Patients younger than 6 years of age were excluded because of potentially unreliable pulmonary function
testing.
Themodel development segment of the cohort, which included a random subset of 80% of patients, consisted of 24 704
patients who contributed a total of 896 088 FEV1 observations. Demographic and clinical summaries for the develop-
ment cohort are shown in Table 1. The median number of observations per patient was 31 and ranged from 1 to 253.
Per-patient duration of follow-up ranged from 0 to 13 years, with a median of 8.5 and a mean of 7.7. Figure 1 shows repre-
sentative FEV1 trajectories overage available in the dataset. The example profiles, highlighted as black lines, demonstrate
the between-patient and within-patient variability commonly observed in longitudinal lung-function data, as well as the
nonlinear, heterogeneous nature of FEV1 decline specific to CF disease progression.
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TABLE 1 Clinical and demographic composition of the cystic fibrosis data
Characteristics Development cohort (n = 24 704) Validation cohort (n = 6175)
Birth cohort
<1981 5455 (22.1%) 1336 (21.6%)
1981 to 1988 4886 (19.8%) 1220 (19.8%)
1989 to 1994 4476 (18.1%) 1090 (17.7%)
1995 to 1998 2887 (11.7%) 727 (11.8%)
1999 to 2005 4642 (18.8%) 1170 (18.9%)
>2005 2358 (9.5%) 632 (10.2%)
Genotype (F508del mutation type)
Homozygous 11 150 (45.1%) 2851 (46.2%)
Heterozygous 9884 (40%) 2430 (39.4%)
Neither/unknown 3670 (14.9%) 894 (14.5%)
Male gender 12 744 (51.6%) 3211 (52%)
Age at baseline, mean; median (min-max) 16.6; 12.5 (6.0-81.8) 16.5; 12.4 (6.0-79.0)
FEV1 at baseline mean; median (min-max) 79.8; 83.8 (9.3-149.3) 80.1; 82.9 (8.8-143.4)
Medicaid insurance use
At baseline 11 069 (44.8%) 2759 (44.7%)
Ever during follow-up 19 032 (77%) 4789 (77.6%)
Microbiology
Pseudomonas aeruginosa
At baseline 6509 (26.3%) 1646 (26.7%)
Ever during follow-up 18 434 (74.6%) 4649 (75.3%)
Methicillin-resistant Staphylococcus aureus
At baseline 1774 (7.2%) 472 (7.6%)
Ever during follow-up 10 821 (43.8%) 2639 (42.7%)
CF-related diabetes mellitus
At baseline 1961 (7.9%) 490 (7.9%)
Ever during follow-up 7525 (30.5%) 1853 (30%)
Alive through follow-up 23 692 (95.9%) 5927 (96%)
Abbreviations: CF, cystic fibrosis; FEV1, forced expiratory volume in 1 second of percentage of predicted.
The dataset also included binary time-varying measures on Medicaid insurance use, microbiology (infection with
Pseudomonas aeruginosa or Methicillin-resistant Staphylococcus aureus, MRSA) and CF-related diabetes (CFRD) mel-
litus. Summary statistics for these additional variables at baseline and across follow-up are shown in Table 1. There
were 1529 patients with missing data on one or more static covariates who were excluded from the analysis cohort
(Table S1 in Data S2). Because age was used as the time scale, there was left-truncation because individuals were
included only from 2003. Time since baseline (in years) was included in the modeling. Furthermore, all individ-
uals were censored at their age at the end of 2015, at death or at the first year of receiving a lung transplant
if that occurred first. To partially address potential bias due to these design features, the subsequently described
models were adjusted for birth cohort (<1981, 1981-1988, 1989-1994, 1995-1998, 1999-2005, >2005). To account
for irregular sampling due to disease severity, we included numbers of acute pulmonary exacerbations and outpa-
tient visits within the year prior to a given clinical encounter as covariates in the longitudinal models described
below.
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F I GURE 1 Observed forced expiratory volume in 1 second of
percentage of predicted against age at measurement (in years). Five
specific patient profiles, illustrating various patterns of rapid decline
over the lifespan, are shown as black lines
3 MODELING RAPID DISEASE PROGRESSION
In this section, we present the specific form of the nonstationary stochastic process model used to depict age-related
lung-function decline in the CF cohort and show how this model can be used to assess rapid disease progression in an
application. We let Yij be the lung function (FEV1) measurement for the ith patient taken at time point tij, i = 1,… , N;
j = 1,… , ni. Herein, tij is patient age, in years. The stochastic model can be expressed as:
Y𝑖𝑗 = 𝜇i(t𝑖𝑗) + Ui +Wi(t𝑖𝑗) + Z𝑖𝑗 , (1)
where 𝜇i(tij) represents the fixed effects of themodel in Equation (1). Between-patient heterogeneity is incorporated in the
model with a random intercept term Ui, where Ui ∼N(0,𝜔2). The termWi(tij) denotes realizations from the zero-mean,
continuous-time integrated Brownian motion process such that Wi(t) = ∫ t0 Bi(v)𝑑𝑣, where Bi(v) is the rate of change in
lung function at time v depicted as Brownian motion and Bi(0) = 0. The term Zij ∼N(0, 𝜏2) represents independent,
identically distributed measurement error. Expression 𝜇i(tij) can be decomposed as:
𝜇i(t𝑖𝑗) = f (t𝑖𝑗) + Xi(t𝑖𝑗)𝜶. (2)
The design matrix Xi(tij) includes covariates (both static and time-varying as defined in Section 2) and corresponding
parameter vector 𝜶. The function f (tij) is the common shape of (nonlinear) FEV1 trajectories at the population level.
In an effort to balance regression splines and stochastic covariance, we examined different spline basis functions and
knot selections. We selected truncated power splines of cubic degree as defined by Ruppert et al26; using knot locations
(𝜉1 = 12.7, 𝜉2 = 19.2, 𝜉3 = 25.6, 𝜉4 = 32.1, 𝜉5 = 38.5) that were determined by the quantile method, similar to a previous
study.7 We denote the corresponding coefficients for the global polynomial and truncated spline terms as 𝛽0, … , 𝛽3
and b1, … , b5, respectively. We use integrated Brownian motion in place of random slopes, conventionally used in CF
FEV1 modeling, to capture the nonmonotone variation in each patient's lung-function trajectory (Figure 1) and provide
a stochastic function for predictions involving the rate of change. The random slope model often fits data from short
follow-up sequences well, but is too inflexible to capture the patterns of variation seen in long-term follow-up.15 The
integrated Brownianmotion process follows a normal distributionwith covariance function for time points (ages) s and t:
𝛾(s, t) = Cov(Wi(s),Wi(t)) = 𝜎2
min(s, t)2
2
(
max(s, t) − min(s, t)3
)
. (3)
This enables greater flexibility over conventional models, in terms of the shape of realizations, that have been used to
characterize changes in FEV1.27
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We can estimate the rate of change in FEV1 by taking the first derivative with respect to age at a given time based on
Equation (1) and modeling it as a noisy version of Si(t):
S′i(t) ≈
d
𝑑𝑡
Yi(t) = f ′i (t) + Xi
′(t𝑖𝑗)𝜶 + Bi(t). (4)
Herein, S′i(t) is the underlying rate of change at current time t for the ith patient, representing this individual's true
rate of change in lung function. This function can be estimated by terms in Equation (2) that correspond to overall mean
rate of progression f i′(t) and terms involving time-varying covariates and covariate-by-time interactions; Bi(t) represents
Brownian motion obtained from differentiating the integrated Brownian motion processWi(t). Herein, Bi(t)∼N(0, 𝜎2t)
and has covariance Cov(Bi(s),Bi(t)) = 𝜎2min(s, t).
3.1 Model fitting
A stratified random sampling approach was used to partition the CFFPR analysis cohort data into three nonoverlapping
datasets: (i) development; (ii) out-of-sample validation; (iii) masked forecasting (Figure S1 in Data S2). We first randomly
split the cohort into 80% and 20%, representing datasets (i) and (ii), respectively. To create a dataset (iii), a subset of the
cohort from dataset (i) was randomly selected to have the last 2 years of their data masked, to examine forecast accuracy
beyond the period included in the model and compare the forecast values to actual data. This scenario corresponds to
the typical CF setting in which newly accrued patient data would be used to forecast rapid decline on patients with data
already deposited into the registry and part of model fitting/updating.
Maximum likelihood estimates of the model parameters (Table 2) were obtained on dataset (i) using the lmenssp
package in R.28 Although our primary goal is the prediction of rapid decline, we examined parameter estimates for model
coefficients. After accounting for the nonlinear, population-level progression of FEV1 through f ′(t), we found that being
born into a more modern birth cohort corresponded to less rapid FEV1 decline; increased frequency of clinic visits was
associated with higher overall FEV1; longer follow-up, increased frequency of pulmonary exacerbations, being female
and having an infection with P aeruginosa were associated with more rapid decline. Having CFRD and using Medicaid
insurance were associated with slightly less rapid decline (coefficients were relatively small). MLEs of the covariance
parameters indicated large between-patient heterogeneity (?̂?2 = 25.2557) and residual variance (𝜏2 = 69.9562); estimated
variance of the integrated Brownian motion process was 𝜎2 = 0.8747.
Predictive performance for validation datasets (ii) to (iii) was evaluated for the accuracy of FEV1% predicted. TheMet-
rics used were root mean square error (RMSE), mean absolute error (MAE), andmean absolute percentage error (MAPE)
for FEV1% predicted (Table S2 in Data S2). RMSE was 7.8% predicted for held-out patients in dataset (ii), suggesting rea-
sonable predictive accuracy for newly accrued CF patients. Horizons of 0.5, 1, and 2 years were examined for masked
forecasting with dataset (iii). Respective RMSE values were 5.1%, 5.8%, and 6.5% predicted. As shown in the Supporting
Information, MAE and MAPE exhibited similar patterns for both types of validation, suggesting reasonable predictive
accuracy for FEV1. Accuracy improved as years of observed follow-up increased (Figure S2 in Data S2), but was variable
with respect to number of follow-ups (Figure S3 in Data S2).
3.2 Model checking
Diagnostics were examined for standardized empirical residuals, which were computed based on fitted values from the
model in Equation (1). Following notation from Diggle et al,22 we let ri = Yi − f (ti)−Xi𝜶 be the vector of residuals for
the ith patient. The corresponding estimated variance-covariance matrix for Yi is V̂ i = ?̂?2J i + 𝜎2Ri + 𝜏2Ii, where J i is a
ni ×ni matrix of ones; Ri is a ni ×ni matrix with element (j, k) written as:
min(t𝑖𝑗 , t𝑖𝑘)2
2
(
max(t𝑖𝑗 , t𝑖𝑘) −
min(t𝑖𝑗 , t𝑖𝑘)
3
)
,
and Ii is the identity matrix of size ni. We decomposed V̂ i using lower triangular matrix Si such that as V̂ i = SiSTi . Then,
we computed the transformed empirical residual vector r∗i = S
−1
i ri for each patient (i = 1,… ,N).
These standardized residuals were plotted against both the fitted values and age (Figure 2, upper panels). Each plot
includes the LOWESS smoother shown in black, which fell on the horizontal line at zero. Residuals plotted against
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TABLE 2 Parameter estimates and standard errors for the CF dynamic regression model
Parameter (context) Estimate 95% CI
Shape, f (t) 𝛽0 (Intercept) 8.6850 (3.184, 14.186)
𝛽1 (Age) −1.5997 (−2.341, −0.858)
𝛽2 (Age2) 0.5023 (0.437, 0.567)
𝛽3 (Age3) −0.0224 (−0.024, −0.02)
b1 0.0458 (0.043, 0.049)
b2 −0.0308 (−0.033, −0.029)
b3 0.0089 (0.007, 0.011)
b4 −0.0024 (−0.005, 0)
b5 0.0008 (−0.001, 0.002)
Covariate effects, 𝛼 𝛼1 (time since baseline) −0.2843 (−0.419, −0.15)
Ref: F508del homozygote 𝛼2 (F508del heterozygote) −1.3377 (−1.993, −0.683)
𝛼3 (F508del neither/unknown) −3.7539 (−4.715, −2.793)
𝛼4 (Male) −2.2355 (−2.842, −1.629)
Ref: born before 1981 𝛼5 (born 1981-1988) 12.1304 (7.947, 16.314)
𝛼6 (born 1989-1994) 11.5799 (7.195, 15.965)
𝛼7 (born 1995-1998) 14.9403 (10.405, 19.476)
𝛼8 (born 1999-2005) 16.8315 (12.287, 21.376)
𝛼9 (born>2005) 17.5418 (12.804, 22.279)
𝛼10 (FEV1 at baseline) 0.8181 (0.809, 0.827)
𝛼11 (Enzyme use) −0.5294 (−0.634, −0.424)
𝛼9 (Pseudomonas aeruginosa) 0.6668 (0.47, 0.864)
𝛼10 (Methicillin-resistant Staphylococcus aureus) −0.2329 (−0.453, −0.013)
𝛼11 (CF-related diabetes mellitus) −1.0740 (−1.32, −0.828)
𝛼11 (Medicaid insurance use) −0.2293 (−0.373, −0.085)
𝛼11 (Outpatient visits in last year) 0.1211 (0.112, 0.13)
𝛼12 (Acute exacerbations in last year) −0.7478 (−0.777, −0.718)
Ref: F508del homozygote 𝛼13 (F508del heterozygote× age) 0.1615 (0.071, 0.252)
𝛼14 (F508del neither/unknown× age) 0.3640 (0.236, 0.492)
𝛼15 (Male× age) 0.2338 (0.151, 0.317)
Ref: born before 1981 𝛼5 (born 1981-1988× age) 1.0893 (0.872, 1.306)
𝛼6 (born 1989-1994× age) 1.5485 (1.325, 1.772)
𝛼7 (born 1995-1998× age) 1.7227 (1.486, 1.96)
𝛼8 (born 1999-2005× age) 1.8683 (1.636, 2.101)
𝛼9 (born>2005× age) 1.8638 (1.557, 2.17)
𝛼11 (Enzyme use× age) −0.0018 (−0.007, 0.003)
𝛼19 (Pseudomonas aeruginosa× age) −0.0259 (−0.037, −0.015)
𝛼10 (Methicillin-resistant Staphylococcus aureus× age) −0.0072 (−0.018, 0.003)
𝛼20 (CF-related diabetes mellitus× age) 0.0185 (0.009, 0.028)
𝛼11 (Medicaid insurance use× age) 0.0072 (0.001, 0.013)
Variance 𝜔2 (between patient) 25.2557 (22.417, 28.094)
𝜎2 (within patient) 0.8747 (0.862, 0.888)
𝜏2 (residual) 69.9562 (69.744, 70.169)
Abbreviations: CF, cystic fibrosis; FEV1, forced expiratory volume in 1 second of percentage of predicted.
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F IGURE 2 Diagnostics for
standardized empirical residuals from
the cystic fibrosis dynamic regression
model, including residuals vs fitted
values (upper-left panel), residuals vs
the time variable, age (upper-right
panel), histogram with standard normal
density overlay (lower-left panel), and
quantile-quantile plot (lower-right
panel)
F IGURE 3 Variogram based on the raw residuals against separation in time, as years (left panel) with the dashed lines representing
total process variance (320.61); the smooth black line is the empirical variogram function with upper and lower dashed lines (229.92 and
59.07, respectively) marking partitions for between-patient variance, within-patient variance, and residual error. Variogram for transformed
residuals against the lag based on the transformed time scale (right panel). Each plot was averaged over bin sizes of 0.017 (corresponding to
weekly intervals); bins with fewer than 20 residuals were excluded
age suggested that the mean of the residuals is about zero; however, the spread of the residuals decreased with age,
indicating heteroscedasticity. The residuals exhibited a symmetric bell-shaped distribution (lower-left panel), but the
quantile-quantile plot (lower-right panel) implied heavier tails than the standard normal distribution.
Covariance assumptions (Figure 3) based on the fitted model were examined using empirical variograms for longi-
tudinal data.29 The variogram for raw residuals ri was calculated using a bin size corresponding to weekly intervals and
represents the variance of the difference between residuals within patients at time lags from 0 to 13 years (left panel, gray
line). This variogram was used to partition total process variance into three components of variation: between patient
(28%), within patient (53.3%), and residual error (18.4%). The smoothed empirical variogram fit (black line) suggests that
the correlation between paired lung functionmeasures decreased as separation in time increased. Although this function
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did not have an asymptote, the shape is similar to what has been shown with longitudinal FEV1 modeling in the Danish
CF registry.15 Covariance assumptions were examined using a variogram of the transformed residuals r∗i (right panel).
Empirical variogram ordinates were obtained using the formulas presented by Diggle et al.22 Random deviation about
1 implies that the model fits well. Ordinates increased up to about lag 0.1, then remained relatively steady, indicating a
similar correlation through the range of lags, until a sharp drop around lag 0.5, at which point the function increased.
Transformations (eg, log) of the response variable were considered to stabilize the variance. Modeling the data only
from age 6 to 30 years old avoided presence of fitted values around 50 shown in Figure 2 (upper-left panel), and similar
diagnostic resultswere foundwhen subsetting the data so that only F508del homozygoteswere included. Both alternatives
gave otherwise similar results as modeling the primary analysis cohort. Using time since baseline to form the model
covariance resulted in a similar model fit and diagnostics. Specifying alternative distributions for the random effects did
not impact results. Different numbers and locations of knots were considered, and the presented model had the best fit.
More detail on the alternative knot settings and corresponding results are provided in Table S3 in Data S2.
4 PREDICTING RAPID DISEASE PROGRESSION
Conditional distributions from the model were used to form predictions of each patient's true lung function, of which
FEV1 is assumed to be an unbiased proxy. These conditional distributions have been shown to be Gaussian given the
previously described linearmixed effectsmodel assumptions.22 Forms of these Gaussian distributions are detailed therein
(equations 4.8-4.12).22
4.1 Predictive probabilities of rapid decline
We let the covariate history up to a given time t of each patient be represented as i(t) = {Xi, (tij, yij) : tij ≤ t}. Based on
this history, we can construct a predictive probability distribution for S′(tik) (defined in Equation 4) being below a given
threshold 𝛿 at time tik with estimation of parameter vector ?̂? = (𝜷, b̂, ?̂?, 𝜏2):
p∗i (t𝑖𝑘) = P(S
′
i(t𝑖𝑘) < 𝛿|i(t𝑖𝑘)) = P(Bi(t𝑖𝑘) < 𝛿 − f ′i (t) − Xi′(t𝑖𝑗)?̂?|i(t𝑖𝑘)), (5)
where S′i(t𝑖𝑘) is the true underlying rate of change in lung function; 𝛿 is the threshold (in % predicted/year) for identifying
rapid decline; 𝜇′i (t𝑖𝑘) is the first-order derivative of 𝜇i(tik) with respect to time tik.
By looking at the derivative of an individual's estimated lung-function trajectory overage, we can see their rate of
decline at different ages and hence identify periods of faster decline, the age of peak decline and other clinically rele-
vant target functions. These thresholds can be used to assign a level of rapid decline overall or specific to the individual
patient. Figure 4 shows an example with 𝛿 = − 1.5 % predicted/year; values below this rate would imply the patient is in
rapid decline.
Although uniform thresholds (hereafter, denoted as 𝛿c) can aid clinicians in evaluating whether a patient is in a period
of rapid decline, it may also be desirable to assess the patient's risk of experiencing peak decline at a given time point.
Peak decline can be defined based on the derivative of a given patient's lung-function trajectory as
t∗i = argmint
{𝜇′i (t) + Bi(t)}. (6)
In application, 𝛿i(t∗i ) is the estimate of individualized peak decline obtained by plugging in the model-based esti-
mates for the parameters and solving for time. For example, Figure 4 shows a lung-function trajectory with peak decline
(−3% predicted/year) occurring ∼18.5 years of age.
4.2 Bootstrapping procedure
We used a simulation-based bootstrapping algorithm for functions involving complicated derivatives,30 to acquire a
95% CI for the predictive probabilities. Let 𝜇Bi(t𝑖𝑘) and 𝚺ni denote the mean and covariance matrix for Bi(tik) defined in
Section 3, giveni(tik). Assume 𝜇Bi(t𝑖𝑘) satisfies.√
ni(?̂?Bi − 𝝁Bi)
D
→Nni (0,𝚺ni ), (7)
10 SZCZESNIAK et al.
F IGURE 4 Underlying rate of change in lung function S′(t)
from childhood until early adulthood over time t depicted as a
smooth curve (black line), indicating periods with a loss of lung
function (values below the dashed horizontal line at 0, indicating
when the slope is negative) with examples of a uniform threshold of
rapid decline (−1.5% predicted/year, dashed-dotted line) and peak
decline (−3% predicted/year, marked as “X”)
where𝝁Bi denotes the vector𝜇Bi1 , 𝜇Bi2 ,… , 𝜇Bini , which is estimated by ?̂?Bi from themodel.We conducted the bootstrapping
process for each patient via the following steps:
Draw independent samples (l = 1,… ,L): Qnil ∼ Nni(0, ?̂?ni), where ?̂?ni is the estimate of 𝚺ni from the model.
Compute 𝝁∗Bi = ?̂?Bi + n
−1∕2
i Qnil. In our application, we used L = 100.
1. For each sample Qnil and given time point tik, calculate pi(t𝑖𝑘|𝜇∗Bi(t𝑖𝑘) ) from Equation (5) using 𝜇∗Bi(t𝑖𝑘) and mean-squared
error as M̂SE
∗
ni = L−1
L∑
l=1
(
pi
(
t𝑖𝑘|𝜇∗Bi(t𝑖𝑘)) − pi(t𝑖𝑘|B̂i(t𝑖𝑘)))2.
2. Construct the (1− 𝛼)× 100%CI for the predicted probability of rapid decline at time tik as pi(t𝑖𝑘|B̂i(t𝑖𝑘))±z1−𝛼∕2√M̂SEni .
We used 𝛼 = 0.05.
5 INDIVIDUAL PATIENT PREDICTIONS
Individual patient predictions from theCFdynamic regressionmodel, alongwith 95%prediction intervals for longitudinal
FEV1 and the corresponding rate of change, are shown for two patients in Figure 5. Row 1 corresponds to a female F508del
heterozygous patient. Beginning with the leftmost plot, the gray dots represent her observed FEV1 data overage; the fitted
trajectory is the solid black line with 95% CI in gray bands. The Brownian motion nowcast density (middle plot) shows
declining lung-function overage, punctuated by a sharp drop around 12-years-old; this plot shows the fluctuating rate of
disease progression. The gray portions represent nowcasts of FEV1 and rate of change, while the red fitted curves and
prediction intervals provide a short-term forecast of FEV1 and rate of change assuming the data over the last 2 years were
unobserved. Her real-time predicted probability of rapid decline (rightmost plot) is variable overage and coincides with
the predicted rate of progression, with periods of highest risk around 11 to 12 years old and again from 17 to 19 years old.
Her forecasted probability of rapid decline, taken with the last 2 years of her data masked, agrees with the nowcasted
values that incorporate the observed data.
Another patient (male F508del homozygote) has predictions shown in Row 2 of Figure 5. Compared with the pre-
vious patient, his progression is steadier overage. His estimated Brownian motion process was less variable than the
female (middle panel). His risk of rapid decline remained low through adolescence based on nowcasted values. The
corresponding forecasted risk of rapid decline was slightly higher than nowcasted around age 11 years.
Each row of Figure 6 corresponds to these two patients, showing their real-time predictive probability of rapid decline
defined as 𝛿c <−3%predicted/year (first column) andpersonalized threshold, 𝛿i(t∗i ) (second column).Within each patient,
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F I GURE 5 Dynamic predictions for a female F508del heterozygous patient (first row) and a male F508del homozygous patient
(second row). Observed FEV1 (black dots) against age is shown for each patient (first column) with estimated lung function S(t) and 95% CI
(gray bands) and 2-year forecasted lung function (red line with prediction bands); underlying rate of change S′(t) estimated by Brownian
motion (second column), including prediction intervals and forecasts; predictive probabilities of rapid decline (defined as 𝛿c = −1.5%
predicted/year) (third column), including bootstrapped 95% CI and forecasts. CI, confidence interval; FEV1, forced expiratory volume in 1
second of percentage of predicted [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 6 Predictive
probabilities of rapid decline (defined as
𝛿c <−3% predicted/year) (first column)
corresponding to patients in Figure 5
(first row is the female F508del
heterozygote; second row is the male
F508del homozygote); personalized
threshold 𝛿i (ti*) is shown for each
patient (second column), including
bootstrapped 95% CI and forecasts. CI,
confidence interval [Color figure can be
viewed at wileyonlinelibrary.com]
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TABLE 3 Predictive accuracy as area under the ROC curve (AUC) from empirical simulations
AUC: 50th percentile (25th, 75th)
Structure
Threshold for rapid
decline, % predicted/year 2-year slice 5-year slice 10-year slice Complete data
Full model 𝛿c = −1.5 0.745 (0.740, 0.751) 0.749 (0.743, 0.752) 0.746 (0.744, 0.749) 0.745 (0.741, 0.747)
𝛿c = −3.0 0.747 (0.742, 0.753) 0.757 (0.753, 0.761) 0.755 (0.753, 0.758) 0.754 (0.751, 0.756)
𝛿i(t∗i ) 0.821 (0.816, 0.825) 0.851 (0.847, 0.856) 0.827 (0.823, 0.831) 0.817 (0.814, 0.822)
No adjustment
for time since
baseline
𝛿c = −1.5 0.985 (0.983, 0.987) 0.754 (0.750, 0.758) 0.716 (0.713, 0.719) 0.710 (0.707, 0.713)
𝛿c = −3.0 0.988 (0.986, 0.989) 0.780 (0.775, 0.785) 0.722 (0.719, 0.725) 0.713 (0.710, 0.716)
𝛿i(t∗i ) 0.994 (0.993, 0.996) 0.843 (0.837, 0.852) 0.779 (0.774, 0.783) 0.754 (0.749, 0.758)
predictive probabilities for the target values were similar over time; however, the predictive probability of a given patient
reaching peak decline varied over time. Peak decline estimates for displayed female andmale patients were 𝛿i(t∗i ) = −2.51
and −1.66% predicted/year, respectively.
5.1 Empirical simulations
We investigated properties of the predictive probabilities of rapid decline from the model using simulation studies. We
randomly selected 500 patients from the training cohort data; thus, the number of observations varied by patient. We
used their covariate information as explanatory values in the simulation study. Random effects Ui, Wi(tij) and Zij were
simulated from their corresponding distributions assumed in the model fitting. Parameters were set to their estimated
values from Table 2. We performed 150 replications using the covariate information and random effects distributions
above, to generate the Yij values. We ran the model on each replication batch of the Yij values. Accuracy of the predictive
probabilities for nowcasting rapid decline was assessed using area under the ROC curve (AUC). This can be achieved for
a given patient at time tik by defining an indicator function:
A𝑖𝑡𝑖𝑘 =
{
1, Bi(t𝑖𝑘) + 𝜇′i (t𝑖𝑘) < 𝛿
0, o∕w
(8)
Herein, A𝑖𝑡𝑖𝑘 can be evaluated against p∗i (t𝑖𝑘) to yield AUC estimates, where p
∗
i (t𝑖𝑘) is estimated based on Equation (5).
We examined AUC estimates for uniform thresholds 𝛿c = − 1.5% predicted year, −3% predicted/year, and personal-
ized peak decline 𝛿i(t∗i ) (Table 3). The impact of not adjusting for extent of follow-up (incorporated in the model as time
since baseline) was examined. Scenarios were considered in which limited data were available per patient by randomly
selecting 2-, 5-, or 10-year intervals of data. Adjusting for time since baseline produced the most consistent AUC esti-
mates across slices, which is likely expected given that simulations were generated including this variable. Not adjusting
for follow-up and limiting observation periods to 2 years or less increased AUC estimates; this is likely explained by
the choice of the Brownian motion process, which has increasing variation over follow-up that may not be realized
over shorter durations. Using complete data, the uniform thresholds had a lower AUC than the threshold based on the
individualized peak decline.
5.2 Prediction model app
The R Shiny package was used to develop an interactive clinical tool for predictions based on the presentedmodel specific
to 𝛿c = − 1.5% predicted/year. The latest prototype of the app with individualized predictions for the forecast validation
cohort is hosted at http://predictfev1.com.Aproof-of-principle study describing how this prototype versionwas developed
using clinician feedback has been described elsewhere.31 A still image from the app is shown (Figure 7) for a female
patient with no F508del alleles with first available observed FEV1 at age 7.3 years, born during 1995 to 1998, and baseline
FEV1 of 96.9% predicted. The patient experienced FEV1 loss that became more severe with age and was at high risk by
∼ 8-years-old. Her risk varied over follow-up, but increased again at 16-years-old. The gray shaded area includes data used
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F I GURE 7 R Shiny app (screenshot) displaying real-time risk of rapid decline in the individual cystic fibrosis patient (female case with
genotype having no F508del alleles). The left panel provides user-specific selections for patients and demographic/clinical characteristics.
The middle panel includes graphs corresponding to lung-function trajectory, rate of change, and predictive probability of rapid decline
(threshold set to 𝛿c = −1.5% predicted/year). The third panel shows heat map of covariates included in the model for rolling numbers of
exacerbations and clinic visits in year to each clinical encounter, infection with MRSA, use of state/federal insurance, diagnosis of cystic
fibrosis-related diabetes, and infection with Pseudomonas aeruginosa. MRSA, Methicillin-resistant Staphylococcus aureus [Color figure can be
viewed at wileyonlinelibrary.com]
for training the prediction model, while the red shaded area covers the 2-year forecast period. This patient had relatively
few pulmonary exacerbations (indicated by blue-green shading on rightmost upper panel) and increased her clinic visit
frequencywith age. The gray/red dots in the panel correspond to indicator functions for the covariates. Shewas diagnosed
with CFRD, had lower socioeconomic status (use of Medicaid insurance) and experienced infections with P aeruginosa,
but not MRSA. A description of the app functionality, including patient selection and generating normative data, and an
additional illustration are provided as Supporting Information (Figures S4 and S5 in Data S2).
5.3 Center-level comparison
The prediction model was applied to data collected from patients receiving care between January 4, 2012 and February
27, 2017, at an accredited CF center that currently employs a clinical algorithm to detect time to first rapid decline. Their
algorithm defines the rapid decline at a given visit as a drop in FEV1 of at least 10% predicted from the maximum FEV1
observed over the preceding year.32 Themodel was applied withmodifications for the younger age range andmore recent
birth cohorts present at the center, compared with the entire CFFPR. Rapid decline was defined from the model using
𝛿c = − 1.5% predicted/year. Our goal was to compare the center's definition with the model-based definition of rapid
decline developed in this article, to determine the extent to which these two distinct definitions of rapid declinemay yield
different detection times.
There were 212 patients aged 6 to 22 years old who contributed 3846 observations over the timeframe at the single
CF care center (Table S4 in Data S2). The prediction model detected a similar subgroup of patients experiencing a rapid
decline to those identified using the center-level algorithm (sensitivity: 83%), but detected a different subgroup of patients
who were classified as not experiencing rapid decline (specificity: 64%). The prediction model identified 120 out of 145
patients whom the center-level algorithm identified experiencing a rapid decline over the study period. Mean (range) of
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the timing of rapid decline based on the model and center-level algorithm were 12.54 (6-19.5) and 13.19 (6.3-20.7) years
of age, respectively. Therefore, rapid decline was identified roughly 8 months earlier using the model, compared with the
clinical algorithm (mean difference: 0.65 years, 95% t-interval: 0.41-0.89).
6 DISCUSSION
We have presented a statistical method for monitoring and detecting rapid disease progression depicted by long,
irregularly observed time series, tailoring the approach to CF lung disease. This article demonstrates how estimated rate of
change in an individual's lung-function trajectory can be used to establish both clinically meaningful and patient-specific
thresholds that, when coupled with probabilistic predictive inference and translated through an app, provide a useful
medical-monitoring approach. Gaussian linear mixed models with nonstationary stochastic processes provide a natural
framework for formulating targets like rapid decline or peak decline in chronic disease settings. The resulting predictive
probabilities, which were shown to be well calibrated based on held-out data, are clinically informative risk measures.
Predictions shown were made at once over a 2-year horizon; however, the approach could be used successively across
the horizon as new clinical information is accrued.
This novel application examined over 30 000 patients “at-risk” for rapid decline and showed the substantial hetero-
geneity in FEV1 progression among patients and within a given patient's trajectory. For example, the two cases shown
in Figures 5 and 6 have distinct lung-function trajectories and risk profiles for rapid decline. Although previous studies
identified early adolescence/adulthood as high risk,3,8,9 we found that risk of rapid decline varied considerably between
patients and within a given patient during this period. Our approach and application provides a pillar in CF diagnostic
medicine by focusing on a modern, comprehensive cohort, and development of a prognostic aid. We have confirmed the
attenuated decreases in FEV1 that have been shown previously, further expanded the timeframe to predict risk beyond
early adulthood and provided those predictions according to individual patient characteristics. This is the basis on which
the presented cases among the 4849 profiles shown in the web application, can differ considerably yet may go unno-
ticed without real-time monitoring tools. Our findings suggest that it may be easier, in practice, to predict whether a
patient has hit their nadir (peak decline), compared with a specific threshold of decline. This result could be attributed
to each patient's trajectory having a nadir, but not everyone may reach the prespecified uniform threshold. It is also
possible that uniform thresholds could be of smaller magnitude and generally more difficult to predict within a noisy
time series.
Empirical simulations of our model indicate that long-term follow-up on some portion of patients in the cohort may
be necessary to understand actual predictive performance across targets (uniform or personalized). Predictive probabil-
ities for a target function involving S′(t) cannot be verified for accuracy in real data applications, given the lack of a
“gold standard.” Care guidelines recommend quarterly “well” visits for patients with CF.33 Our analysis excluded 4.7% of
the overall cohort due to missing covariate data, which consisted primarily of individuals who were older (Table S1 in
Data S2). Bias due to irregular “sick” visits is not directly addressed with our approach; however, a recent assessment of
various model strategies applied to irregularly sample longitudinal data found that MLEs frommixed effects models had
less bias, compared with estimates from other model types.34 Jointly modeling follow-up in the presented model could
further alleviate this issue. Given that the response variable FEV1 has measurement error, it is possible that including
baseline FEV1 as a covariate and having Ui as a random intercept induce bias. We examined models, each excluding one
of these terms, but found worse model fit and predictive accuracy.
Sensitivity analyses of subcohorts according to genotype and age indicated that the model tended to underestimate
FEV1 from individuals with a mild or uncharacteristic CF phenotype, highlighting the difficulty in making predictions
about these subpopulations. Regression diagnostics from the CFFPR application also indicated violations to constant
variance, which can create problems with model coefficient estimates, standard errors, and assumptions regarding
specification of Wi(tij) as integrated Brownian motion. Although lmenssp does not contain direct remedies for this
issue with non-constant variance, it offers extensive selections for random effects to alleviate the issue with covariance
specification. We examined alternative (differentiable) specifications and found model fitting and prediction were best
using the presented structure based on BIC, AIC, and validation metrics. Furthermore, the formulation of the predictive
probabilities wherein Wi(tij) is a stationary process results in a process for Bi(tij) that manifests unrealistic rates of dis-
ease progression. Empirical simulations show reasonable nowcasting performance; however, other processes need to be
examined for long-term forecasting due to the increasing variation that Brownian motion exhibits over follow-up. The
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decreases in estimated AUC that correspond to longer duration of follow-up (Table 2) may also be attributable to possible
heteroscedasticity from the application of the model (Figure 2).
The integrated random walk specified in our model is locally linear, but has continuously changing slope, which
enabled detection of localized, sharp changes in the FEV1 trajectory, facilitating our aim of obtaining real-time predictive
probabilities for monitoring rapid decline. An alternative approach would be to use a segmented linear mixed effects
model with random change points, which can also be implemented in R.35 Mixtures of piecewise linear models of this
form have been applied to classify CF patients aged 6 to 25 years, according to high-magnitude changes in the slope of
observed longitudinal FEV1.4 This type of random change-point model elucidates the age at which maximal FEV1 loss
tends to occur in a population or subpopulations of individuals from childhood to early adulthood and seeks to identify
this one-time event (ie, one change point per patient). Extending the approach to encompass possibly multiple random
change points per patient to identify one or more bouts of rapid decline, as opposed to a single maximal loss, provides
additional localized detection commensurate with our case-study goals. Despite this flexibility, the approach assumes
underlying smoother trajectories than those obtained from integrated Brownianmotion, whichmore reasonably captures
the “saw-tooth” variation found in CF FEV1 (Figure 1). Thus, segmented modeling potentially decreases the sensitivity
with which real-time rapid decline may be detected.
The approach undertaken in our study has important distinctions from past examples aimed at using biomarker
trajectories to predict clinically meaningful changes in non-CF contexts that involve classification-based solutions.
Although Foulkes et al19 also used a Gaussian linear mixed effects model in one of their approaches, they assumed
variation in longitudinal trajectories could be described by a random intercept and slope model, where the latter
term simplifies to Wi(tij) = bitij rather than integrated Brownian motion as we specified in Equation (1). This sim-
plification may not be reasonable for long sequences of repeated measurements over time,36 especially for a context
like CF in which the FEV1 biomarker measurements are correlated for over 15 years.7,15 The multivariate approach
taken by Li and Gatsonis21 could be adapted to the univariate setting in our case study, but additional work would be
needed to incorporate covariate information, as this is not included in their current formulation, and clinical interpre-
tation for monitoring purposes may be limited if explanatory (input) variables for predictive probabilities are confined
to scores.
Finally, by translating this model and approach into a point-of-care tool, there are several implications for clini-
cal care and shared decision making, as well as various strategies for improving the clinical utility of the app. Having
a substantial risk of rapid decline (eg, predictive probability >0.80) could serve as a trigger to initiate more frequent
clinical visits, assessments for infections or mobile reporting of cough symptoms. The approach could complement
methods to monitor patients outside the clinical setting, such as the efforts made to collect at-home spirometry.37 The
web application could be expanded to facilitate shared decision making between the provider and patient, enabling
the patient to view her accrued data and risk of rapid decline. Real-time updating could be accomplished by inte-
grating the application with electronic health record data as it is accrued at the center level. Earlier developments on
joint modeling and prostate cancer recurrence were implemented in an online calculator that can be used to assess
real-time risk.24 As modulators become more available which correct the underlying defect of CF, it will be critical
to update the model using newer data, accounting for these novel therapies and changes to clinical care. The prog-
nostic utility of the model could be compared with current clinical algorithms for the treatment of rapid decline in a
prospective study. As more statisticians translate findings from prediction models into point of care through R Shiny and
other technologies, additional work will be needed to communicate risk measures from clinical dashboards to providers
and patients.38
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